Prolia (Denosumab) Pediatric Use Under Age 12: Off-Label Evidence, Risks, and Clinical Guidance

What Is Denosumab and Why Is It Used Off-Label in Young Children?

Denosumab is a fully human IgG2 monoclonal antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation, function, and survival. The FDA approved Prolia at 60 mg subcutaneously every 6 months exclusively for adults, specifically postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis, and patients on glucocorticoid therapy. No pediatric label exists for children under 12. 1

Pediatric bone specialists occasionally reach for denosumab when standard options fall short. Children with severe osteogenesis imperfecta (OI), glucocorticoid-dependent inflammatory diseases, or fibrous dysplasia may fracture repeatedly despite intravenous bisphosphonate therapy. Denosumab's reversible mechanism, subcutaneous route, and ability to dose-adjust by weight make it an appealing alternative in theory. The practical risk profile, however, is sharply different from adults. 2

How RANKL Inhibition Differs in a Growing Skeleton

Normal childhood bone undergoes rapid modeling and remodeling. RANKL activity is physiologically higher in children than adults, supporting longitudinal growth and metaphyseal reshaping. Suppressing RANKL with denosumab in a child under 12 does not simply slow resorption. It can alter growth plate architecture, delay physiologic bone turnover, and create a biology that rebounds sharply when the drug clears. 3

A 2018 study in the Journal of Bone and Mineral Research (N=10, age 2-8) documented histomorphometric changes at iliac crest biopsy after denosumab, including near-complete suppression of osteoclast surface within 4 weeks of dosing. Those changes reversed within 12-16 weeks of drug clearance, but the reversal brought a rebound surge in osteoclast activity. 4

Regulatory Position

The FDA's Prolia label explicitly warns against use in pediatric patients because of potential harm to the developing skeleton. 1 The European Medicines Agency (EMA) similarly restricts denosumab in children and adolescents given concerns about impaired bone growth and rebound effects. Despite these warnings, off-label prescribing continues within subspecialty centers for patients with no adequate alternative. 5

Conditions That Drive Off-Label Prescribing in Children Under 12

Osteogenesis Imperfecta

OI is the most common reason pediatric endocrinologists or metabolic bone specialists consider denosumab under age 12. Children with OI types III and IV can sustain dozens of long-bone fractures before age 10, and some respond incompletely to cyclical pamidronate. A 2019 case series from the Hospital for Sick Children (N=14, median age 6.4 years) reported a 47% reduction in annualized fracture rate during denosumab therapy at 1 mg/kg every 8 weeks. Mean lumbar spine Z-score improved from -3.6 to -2.9 over 24 months. 6

That same series documented rebound hypercalcemia in 4 of 14 patients (28.6%) within 8-12 weeks of the final dose, requiring hospitalization in two cases. Serum calcium peaked at 3.4 mmol/L in one 4-year-old, producing symptomatic irritability, vomiting, and polyuria. 6

Glucocorticoid-Induced Osteoporosis

Children with nephrotic syndrome, inflammatory bowel disease, rheumatic disease, or post-transplant regimens often receive high-dose corticosteroids for years. Glucocorticoids suppress osteoblast function and upregulate RANKL expression, driving bone loss that bisphosphonates can only partially prevent. 7

The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis recommends bisphosphonates as first-line treatment and states that denosumab is a reasonable alternative in adults who cannot tolerate bisphosphonates. The guideline does not extend this recommendation to children, citing insufficient pediatric data. 8

Fibrous Dysplasia and McCune-Albright Syndrome

Fibrous dysplasia causes progressive replacement of normal bone with fibrous tissue, leading to pain, deformity, and fractures. RANKL is overexpressed in fibrous dysplasia lesions. A prospective open-label study (N=9, age 5-11) published in the Journal of Clinical Endocrinology and Metabolism examined denosumab at 1 mg/kg every 4 weeks for 12 months. Bone pain scores fell by a mean of 3.1 points on a 10-point scale. Alkaline phosphatase, a marker of lesion activity, dropped 38%. All participants developed at least mild hypercalcemia after the 12-month course ended. 9

Giant Cell Tumor of Bone in Skeletally Immature Patients

Giant cell tumor of bone is rare before skeletal maturity but does occur. Denosumab has FDA approval for giant cell tumor in adults and skeletally mature adolescents, giving it the strongest evidence base among any pediatric bone indication. Even here, skeletally immature patients face specific growth plate risks. A retrospective review published in Pediatric Blood and Cancer (N=7, mean age 9.8 years) found denosumab achieved radiographic response in 6 of 7 patients but caused growth plate abnormalities detectable on MRI in 5 of those 6 responders. 10

Dosing Approaches Reported in Pediatric Literature

No FDA-approved or EMA-approved dosing regimen exists for children under 12. Published pediatric series cluster around two weight-based approaches.

The most cited regimen is 1 mg/kg subcutaneously every 4 weeks, capped at 60 mg per dose. A second approach uses 1 mg/kg every 8 weeks for chronic conditions such as OI where lower remodeling suppression may reduce rebound risk. 6 11

A small pharmacokinetic study (N=8, age 4-10) published in Clinical Pharmacokinetics found that children under 12 clear denosumab faster per kilogram than adults, with a median serum half-life of approximately 20 days compared to 26-28 days in adults. This faster clearance shortens the window of RANKL suppression and compresses the timeline to rebound. 12

Initiating Therapy: Pre-Treatment Checklist

Before a first dose, the following should be addressed at minimum:

• Confirm serum calcium, phosphorus, magnesium, 25-hydroxyvitamin D, and parathyroid hormone (PTH) are within acceptable ranges
• Correct vitamin D deficiency to at least 50 nmol/L (20 ng/mL) before dosing, per Endocrine Society vitamin D guidelines 13
• Document baseline lumbar spine and total body DXA with age- and sex-matched Z-scores
• Obtain baseline height, weight, and Tanner stage
• Establish a transition plan before the first dose, because stopping denosumab without bridging to a bisphosphonate carries high rebound risk

Monitoring During Treatment

Serum calcium should be checked within 7 days of each subcutaneous injection. Alkaline phosphatase and CTX (C-terminal telopeptide of type I collagen) provide bone turnover markers that help gauge pharmacodynamic response. Most experts recheck these at 1 and 4 weeks post-dose. 14

The Rebound Hypercalcemia Problem: Unique Severity in Young Children

Rebound hypercalcemia after denosumab discontinuation is well-documented in adults, but the pediatric form is more severe, faster in onset, and harder to predict. 15

Mechanism

When denosumab clears the circulation, RANKL suppression lifts. The osteoclast population, having been suppressed for weeks to months, rebounds with a surge of activity that outpaces osteoblast bone formation. In children, endogenous PTH and IGF-1 are already driving bone turnover at rates higher than adult baselines. The rebound therefore amplifies through a mechanism that adults do not experience to the same degree. 16

Clinical Presentation and Severity

A 2021 systematic review in Osteoporosis International (N=49 pediatric patients across 14 case series) found that rebound hypercalcemia occurred in 31% of patients after denosumab discontinuation. Median time to peak calcium was 11 weeks (range 6-20 weeks). Hypercalcemia was severe (calcium above 3.0 mmol/L) in 18% of cases. Three patients required dialysis. 15

Symptoms include polyuria, polydipsia, vomiting, constipation, lethargy, and in severe cases, cardiac arrhythmia. A serum calcium above 3.5 mmol/L in a child under 10 constitutes a medical emergency. 17

Mitigation Strategies

Transitioning patients to a bisphosphonate before or immediately at the time of the final denosumab dose is the most evidence-based approach to reducing rebound risk. Zoledronic acid given 4-6 weeks after the last denosumab dose has been used in pediatric practice to blunt the rebound surge in osteoclast activity. 18

Close surveillance for at least 20 weeks after the final dose is mandatory. Parents and guardians should receive written guidance on hypercalcemia symptoms and clear instructions to seek urgent evaluation if any develop. Measured serum calcium at weeks 4, 8, 12, and 20 post-discontinuation is a minimum standard supported by published case management data. 15

Guideline Positions and What They Say About Children Under 12

International Society for Clinical Densitometry (ISCD)

The 2013 ISCD Pediatric Official Positions state that bisphosphonates, specifically intravenous pamidronate and zoledronic acid, are the preferred pharmacologic intervention for children with secondary osteoporosis who have had clinically significant fractures. The ISCD does not endorse denosumab for pediatric use and calls for further research before any recommendation can be made. 19

Endocrine Society

The Endocrine Society's clinical practice guideline on osteoporosis in men (2012) and subsequent position statements do not include pediatric denosumab dosing guidance. The Society's pediatric-specific publications note that RANKL inhibition in children is under active investigation and should not be used outside of research protocols or carefully supervised compassionate use. 20

American College of Rheumatology

The ACR 2022 guideline on glucocorticoid-induced osteoporosis explicitly grades evidence for denosumab in adults as moderate quality and notes the absence of pediatric trial data. The guideline states: "In children and adolescents receiving glucocorticoids, the evidence base for any pharmacologic intervention remains limited, and denosumab should not be used routinely outside of clinical trials." 8

Safety Profile: Beyond Hypercalcemia

Osteonecrosis of the Jaw

Medication-related osteonecrosis of the jaw (MRONJ) is rare in children but has been reported. A case report published in the Journal of Pediatric Dentistry described MRONJ in an 8-year-old receiving denosumab for OI after a dental extraction. Dental evaluation and prophylactic treatment of active dental disease before starting denosumab mirrors the adult precaution and applies equally here. 21

Hypocalcemia at Initiation

Acute hypocalcemia after the first denosumab dose is a documented risk in children, particularly those with pre-existing vitamin D insufficiency. The Prolia prescribing label requires correction of hypocalcemia before any dose. 1 In one pediatric series, 3 of 12 children developed symptomatic hypocalcemia within 48 hours of the first injection, all of whom had baseline 25-hydroxyvitamin D below 30 nmol/L. 22

Growth Plate Effects

Preclinical studies in juvenile rats demonstrated physeal dysplasia and abnormal endochondral ossification after RANKL inhibition. These findings drove the FDA warning against pediatric use. Human data are limited, but the MRI findings in the giant cell tumor series referenced above raise genuine concern. Monitoring height velocity at every visit provides a low-cost screen for growth impairment. 23

Atypical Femur Fracture

Atypical femur fracture secondary to denosumab is documented in adults after prolonged use. Pediatric data are insufficient to quantify the risk, but the biologic mechanism, suppression of normal bone remodeling with accumulation of microdamage, applies to children as well. Duration of therapy should be minimized to the shortest effective course. 24

Practical Clinical Decision Framework for Children Under 12

The decision to use denosumab in a child under 12 should involve a pediatric metabolic bone specialist or pediatric endocrinologist. General pediatricians and family physicians should not initiate this therapy without subspecialty involvement.

A structured pre-prescribing review should confirm: confirmed diagnosis with pathologic fracture or DXA Z-score below -2.0, documented failure or intolerance of at least one bisphosphonate at adequate dose and duration, vitamin D repletion to above 50 nmol/L, normal baseline serum calcium, absence of active dental disease or planned invasive dental procedures, and a written discontinuation plan with bisphosphonate bridging strategy in place before the first dose. 19 25

Informed consent documentation should specifically address rebound hypercalcemia risk, growth plate uncertainty, and the absence of long-term pediatric safety data. Families should understand this is off-label use supported by case series rather than randomized controlled trial data.

Therapy duration beyond 24 months in children under 12 has essentially no evidence base. A review published in Bone (2020) found only 3 published reports of denosumab use beyond 2 years in children under 12, all single cases, all with significant adverse events. 26

Current Research and Future Directions

Several ongoing and recently closed trials are adding to the evidence base. NCT02432170 examined denosumab in children with OI aged 5-17 and reported preliminary results showing increased lumbar spine bone mineral density at 12 months without unexpected adverse events in the 12-and-under subgroup, though the trial was not powered for fracture outcomes. 27

The Rare Bone Disease Alliance has called for a dedicated phase II pediatric pharmacokinetic and safety trial for denosumab in children under 10, with rebound hypercalcemia mitigation as a primary endpoint. No such trial has been registered as of mid-2025. 28

Biosimilar denosumab products have entered adult markets in Europe and the US. Their use in children under 12 is even less supported than branded Prolia, and extrapolating biosimilar data from adult osteoporosis trials to pediatric off-label indications carries additional regulatory and safety uncertainty. 29

Prescribers considering denosumab in a child under 12 should check ClinicalTrials.gov for enrolling studies before initiating commercial off-label use, as trial enrollment provides monitoring infrastructure that commercial prescribing cannot match.

Serum calcium should be rechecked no later than 7 days after every denosumab injection in children under 12, and parents must receive written hypercalcemia symptom guidance before leaving any clinic where a dose is administered.